Avacta Analytical has signed a third distribution agreement with Pall Life Sciences - appointing Pall as the Indian distributor for its market-leading Optim 1000 protein drug development tool.
The Optim 1000 is an innovative analytical instrument that provides biopharmaceutical developers with information about the viability of candidate drug molecules and formulations much earlier in the drug development process, avoiding costly end stage product failures.
The latest collaboration extends the existing North America and South East Asia agreements, granting Pall exclusive marketing and distribution rights to the Optim 1000, to include India.
Alastair Smith, Chief Executive of Avacta Group, commented: “Pall has proved an excellent partner for Avacta, and the success of our existing collaborations in North America and South East Asia was a major factor in the decision to appoint the Company as the sole distributor for the Optim 1000 in India. The Indian biopharma industry is growing rapidly, offering exciting new opportunities, and we look forward to working with Pall in this new territory.”